MedTrace Logo

Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB Patients

NCT06457477 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-06-20

No results posted yet for this study

Summary

This is a prospective study to evaluate the safety and efficacy of Sintilimab (PD-1 antibody) in sequential combination with Peg-IFNα-2b in NA-supressed CHB patients who had previously received Peg-IFNα therapy.

Conditions

Interventions

DRUG

Sintilimab

100mg/10ml/1bottle

DRUG

NAs

tablets

DRUG

Peg-IFNα-2b

180ug/0.5ml/1bottle

Sponsors & Collaborators

  • Beijing 302 Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-15
Primary Completion
2025-12-15
Completion
2025-12-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06457477 on ClinicalTrials.gov